REVIEW article
Front. Cell Dev. Biol.
Sec. Cancer Cell Biology
Volume 13 - 2025 | doi: 10.3389/fcell.2025.1608480
Engineered exosomes: a promising design platform for overcoming cancer therapy resistance
Provisionally accepted
Peng Zhang1Kai Chen2Weifeng Liu3Xiaoying Niu1Xin Wang1
Jiaqiang Wang1Weitao Yao1Xiaodong Tang4
Wen Tian1*- 1Henan Provincial Cancer Hospital, Zhengzhou, China
- 2Zhengzhou University, Zhengzhou, Henan Province, China
- 3Beijing Jishuitan Hospital, Beijing, Beijing Municipality, China
- 4Peking University People's Hospital, Beijing, Beijing Municipality, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Therapeutic resistance is a formidable barrier in cancer treatment, necessitating innovative solutions to enhance drug efficacy. Exosomes, with their unparalleled biocompatibility, low immunogenicity, and robust cargo protection, have emerged as groundbreaking nanocarriers. This review unveils the transformative potential of exosomes in overcoming drug resistance - encompassing chemotherapy, targeted therapy, and immunotherapy - in a wide spectrum of tumors. Through advanced genetic and non-genetic modifications, exosomes can dramatically enhance drug targeting and cytotoxicity, offering unprecedented precision in treatment. We explore state-of-the-art exosome engineering techniques, their revolutionary applications in clinical trials, and their promise as the next frontier in therapeutic innovation. This comprehensive review aims to capture the cutting-edge developments and future directions of exosome-based therapies, positioning them as a cornerstone of next-generation oncology.
Keywords: Engineered exosome, Immunotherapy resistance, chemotherapy resistance, Targeted therapy resistance, precise treatment
Received: 09 Apr 2025; Accepted: 21 Jul 2025.
Copyright: © 2025 Zhang, Chen, Liu, Niu, Wang, Wang, Yao, Tang and Tian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wen Tian, Henan Provincial Cancer Hospital, Zhengzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.